NCT07535606

A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ALN-4915	ALN-4915 will be administered subcutaneously (SC)
DRUG	Placebo	Placebo will be administered SC

Timeline

• Start date: 2026-03-02
• Primary completion: 2027-07-31
• Completion: 2027-07-31
• First posted: 2026-04-17
• Last updated: 2026-04-17

Locations

1 site across 1 country: United Kingdom